[Practical update of total dose compensation in case of temporary interruption of external radiotherapy in the COVID-19 pandemic context].
Identifieur interne : 000125 ( Main/Exploration ); précédent : 000124; suivant : 000126[Practical update of total dose compensation in case of temporary interruption of external radiotherapy in the COVID-19 pandemic context].
Auteurs : D. Azria [France] ; C. Hennequin [France] ; P. Giraud [France]Source :
- Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique [ 1769-6658 ] ; 2020.
Descripteurs français
- KwdFr :
- Abstention thérapeutique (MeSH), Betacoronavirus (MeSH), Carcinome pulmonaire non à petites cellules (radiothérapie), Dosimétrie en radiothérapie (MeSH), Facteurs temps (MeSH), Femelle (MeSH), Humains (MeSH), Infections à coronavirus (épidémiologie), Mâle (MeSH), Pandémies (MeSH), Pneumopathie virale (épidémiologie), Prolifération cellulaire (MeSH), Radiobiologie (méthodes), Tumeurs (anatomopathologie), Tumeurs (radiothérapie), Tumeurs de la prostate (radiothérapie), Tumeurs du col de l'utérus (radiothérapie), Tumeurs du poumon (radiothérapie), Tumeurs du sein (radiothérapie).
- MESH :
- anatomopathologie : Tumeurs.
- méthodes : Radiobiologie.
- radiothérapie : Carcinome pulmonaire non à petites cellules, Tumeurs, Tumeurs de la prostate, Tumeurs du col de l'utérus, Tumeurs du poumon, Tumeurs du sein.
- épidémiologie : Infections à coronavirus, Pneumopathie virale.
- Abstention thérapeutique, Betacoronavirus, Dosimétrie en radiothérapie, Facteurs temps, Femelle, Humains, Mâle, Pandémies, Prolifération cellulaire.
English descriptors
- KwdEn :
- Betacoronavirus (MeSH), Breast Neoplasms (radiotherapy), Carcinoma, Non-Small-Cell Lung (radiotherapy), Cell Proliferation (MeSH), Coronavirus Infections (epidemiology), Female (MeSH), Humans (MeSH), Lung Neoplasms (radiotherapy), Male (MeSH), Neoplasms (pathology), Neoplasms (radiotherapy), Pandemics (MeSH), Pneumonia, Viral (epidemiology), Prostatic Neoplasms (radiotherapy), Radiobiology (methods), Radiotherapy Dosage (MeSH), Time Factors (MeSH), Uterine Cervical Neoplasms (radiotherapy), Withholding Treatment (MeSH).
- MESH :
- epidemiology : Coronavirus Infections, Pneumonia, Viral.
- methods : Radiobiology.
- pathology : Neoplasms.
- radiotherapy : Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, Prostatic Neoplasms, Uterine Cervical Neoplasms.
- Betacoronavirus, Cell Proliferation, Female, Humans, Male, Pandemics, Radiotherapy Dosage, Time Factors, Withholding Treatment.
Abstract
Overall treatment time is an important factor of local recurrence and indirectly of distant evolution, namely in case of protracted treatments. The current pandemic impacts on the duration of radiotherapy if patients under treatments and synchronously suffering from COVID-19. The models used to compensate the total dose in case of temporary treatment interruption are well known but it is of importance in that pandemic context to update and homogenize clinical practice in order to improve local control without increasing normal tissue complications.
DOI: 10.1016/j.canrad.2020.04.001
PubMed: 32307313
PubMed Central: PMC7146696
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Practical update of total dose compensation in case of temporary interruption of external radiotherapy in the COVID-19 pandemic context].</title><author><name sortKey="Azria, D" sort="Azria, D" uniqKey="Azria D" first="D" last="Azria">D. Azria</name><affiliation wicri:level="3"><nlm:affiliation>IRCM, Institut de recherche en cancérologie de Montpellier (U1194), 208, avenue des Apothicaires, 34298 Montpellier cedex 5, France; Inserm, U1194, 208, avenue des Apothicaires, 34298 Montpellier cedex 5, France; Université de Montpellier, centre de recherche U1194, 208, avenue des Apothicaires, 34298 Montpellier cedex 05, France; Fédération universitaire d'oncologie radiothérapie, ICM, institut régional du cancer de Montpellier, rue Croix-Verte, 34298 Montpellier cedex 05, France. Electronic address: david.azria@icm.unicancer.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>IRCM, Institut de recherche en cancérologie de Montpellier (U1194), 208, avenue des Apothicaires, 34298 Montpellier cedex 5, France; Inserm, U1194, 208, avenue des Apothicaires, 34298 Montpellier cedex 5, France; Université de Montpellier, centre de recherche U1194, 208, avenue des Apothicaires, 34298 Montpellier cedex 05, France; Fédération universitaire d'oncologie radiothérapie, ICM, institut régional du cancer de Montpellier, rue Croix-Verte, 34298 Montpellier cedex 05</wicri:regionArea><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Hennequin, C" sort="Hennequin, C" uniqKey="Hennequin C" first="C" last="Hennequin">C. Hennequin</name><affiliation wicri:level="3"><nlm:affiliation>Service de cancérologie-radiothérapie, AP-HP, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75475 Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de cancérologie-radiothérapie, AP-HP, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75475 Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Giraud, P" sort="Giraud, P" uniqKey="Giraud P" first="P" last="Giraud">P. Giraud</name><affiliation wicri:level="3"><nlm:affiliation>Service d'oncologie radiothérapie, AP-HP, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France; Université de Paris, 20, rue Leblanc, 75015 Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service d'oncologie radiothérapie, AP-HP, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France; Université de Paris, 20, rue Leblanc, 75015 Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32307313</idno><idno type="pmid">32307313</idno><idno type="doi">10.1016/j.canrad.2020.04.001</idno><idno type="pmc">PMC7146696</idno><idno type="wicri:Area/Main/Corpus">001669</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001669</idno><idno type="wicri:Area/Main/Curation">001669</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001669</idno><idno type="wicri:Area/Main/Exploration">001669</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Practical update of total dose compensation in case of temporary interruption of external radiotherapy in the COVID-19 pandemic context].</title><author><name sortKey="Azria, D" sort="Azria, D" uniqKey="Azria D" first="D" last="Azria">D. Azria</name><affiliation wicri:level="3"><nlm:affiliation>IRCM, Institut de recherche en cancérologie de Montpellier (U1194), 208, avenue des Apothicaires, 34298 Montpellier cedex 5, France; Inserm, U1194, 208, avenue des Apothicaires, 34298 Montpellier cedex 5, France; Université de Montpellier, centre de recherche U1194, 208, avenue des Apothicaires, 34298 Montpellier cedex 05, France; Fédération universitaire d'oncologie radiothérapie, ICM, institut régional du cancer de Montpellier, rue Croix-Verte, 34298 Montpellier cedex 05, France. Electronic address: david.azria@icm.unicancer.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>IRCM, Institut de recherche en cancérologie de Montpellier (U1194), 208, avenue des Apothicaires, 34298 Montpellier cedex 5, France; Inserm, U1194, 208, avenue des Apothicaires, 34298 Montpellier cedex 5, France; Université de Montpellier, centre de recherche U1194, 208, avenue des Apothicaires, 34298 Montpellier cedex 05, France; Fédération universitaire d'oncologie radiothérapie, ICM, institut régional du cancer de Montpellier, rue Croix-Verte, 34298 Montpellier cedex 05</wicri:regionArea><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Hennequin, C" sort="Hennequin, C" uniqKey="Hennequin C" first="C" last="Hennequin">C. Hennequin</name><affiliation wicri:level="3"><nlm:affiliation>Service de cancérologie-radiothérapie, AP-HP, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75475 Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de cancérologie-radiothérapie, AP-HP, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75475 Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Giraud, P" sort="Giraud, P" uniqKey="Giraud P" first="P" last="Giraud">P. Giraud</name><affiliation wicri:level="3"><nlm:affiliation>Service d'oncologie radiothérapie, AP-HP, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France; Université de Paris, 20, rue Leblanc, 75015 Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service d'oncologie radiothérapie, AP-HP, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France; Université de Paris, 20, rue Leblanc, 75015 Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author></analytic><series><title level="j">Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique</title><idno type="eISSN">1769-6658</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Betacoronavirus (MeSH)</term><term>Breast Neoplasms (radiotherapy)</term><term>Carcinoma, Non-Small-Cell Lung (radiotherapy)</term><term>Cell Proliferation (MeSH)</term><term>Coronavirus Infections (epidemiology)</term><term>Female (MeSH)</term><term>Humans (MeSH)</term><term>Lung Neoplasms (radiotherapy)</term><term>Male (MeSH)</term><term>Neoplasms (pathology)</term><term>Neoplasms (radiotherapy)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (epidemiology)</term><term>Prostatic Neoplasms (radiotherapy)</term><term>Radiobiology (methods)</term><term>Radiotherapy Dosage (MeSH)</term><term>Time Factors (MeSH)</term><term>Uterine Cervical Neoplasms (radiotherapy)</term><term>Withholding Treatment (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Abstention thérapeutique (MeSH)</term><term>Betacoronavirus (MeSH)</term><term>Carcinome pulmonaire non à petites cellules (radiothérapie)</term><term>Dosimétrie en radiothérapie (MeSH)</term><term>Facteurs temps (MeSH)</term><term>Femelle (MeSH)</term><term>Humains (MeSH)</term><term>Infections à coronavirus (épidémiologie)</term><term>Mâle (MeSH)</term><term>Pandémies (MeSH)</term><term>Pneumopathie virale (épidémiologie)</term><term>Prolifération cellulaire (MeSH)</term><term>Radiobiologie (méthodes)</term><term>Tumeurs (anatomopathologie)</term><term>Tumeurs (radiothérapie)</term><term>Tumeurs de la prostate (radiothérapie)</term><term>Tumeurs du col de l'utérus (radiothérapie)</term><term>Tumeurs du poumon (radiothérapie)</term><term>Tumeurs du sein (radiothérapie)</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Tumeurs</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Radiobiology</term></keywords><keywords scheme="MESH" qualifier="méthodes" xml:lang="fr"><term>Radiobiologie</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Neoplasms</term></keywords><keywords scheme="MESH" qualifier="radiotherapy" xml:lang="en"><term>Breast Neoplasms</term><term>Carcinoma, Non-Small-Cell Lung</term><term>Lung Neoplasms</term><term>Neoplasms</term><term>Prostatic Neoplasms</term><term>Uterine Cervical Neoplasms</term></keywords><keywords scheme="MESH" qualifier="radiothérapie" xml:lang="fr"><term>Carcinome pulmonaire non à petites cellules</term><term>Tumeurs</term><term>Tumeurs de la prostate</term><term>Tumeurs du col de l'utérus</term><term>Tumeurs du poumon</term><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Betacoronavirus</term><term>Cell Proliferation</term><term>Female</term><term>Humans</term><term>Male</term><term>Pandemics</term><term>Radiotherapy Dosage</term><term>Time Factors</term><term>Withholding Treatment</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Abstention thérapeutique</term><term>Betacoronavirus</term><term>Dosimétrie en radiothérapie</term><term>Facteurs temps</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Pandémies</term><term>Prolifération cellulaire</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Overall treatment time is an important factor of local recurrence and indirectly of distant evolution, namely in case of protracted treatments. The current pandemic impacts on the duration of radiotherapy if patients under treatments and synchronously suffering from COVID-19. The models used to compensate the total dose in case of temporary treatment interruption are well known but it is of importance in that pandemic context to update and homogenize clinical practice in order to improve local control without increasing normal tissue complications.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32307313</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>10</Day></DateCompleted><DateRevised><Year>2020</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1769-6658</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>3</Issue><PubDate><Year>2020</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique</Title><ISOAbbreviation>Cancer Radiother</ISOAbbreviation></Journal><ArticleTitle>[Practical update of total dose compensation in case of temporary interruption of external radiotherapy in the COVID-19 pandemic context].</ArticleTitle><Pagination><MedlinePgn>182-187</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S1278-3218(20)30096-2</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.canrad.2020.04.001</ELocationID><Abstract><AbstractText>Overall treatment time is an important factor of local recurrence and indirectly of distant evolution, namely in case of protracted treatments. The current pandemic impacts on the duration of radiotherapy if patients under treatments and synchronously suffering from COVID-19. The models used to compensate the total dose in case of temporary treatment interruption are well known but it is of importance in that pandemic context to update and homogenize clinical practice in order to improve local control without increasing normal tissue complications.</AbstractText><CopyrightInformation>Copyright © 2020 Société française de radiothérapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Azria</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>IRCM, Institut de recherche en cancérologie de Montpellier (U1194), 208, avenue des Apothicaires, 34298 Montpellier cedex 5, France; Inserm, U1194, 208, avenue des Apothicaires, 34298 Montpellier cedex 5, France; Université de Montpellier, centre de recherche U1194, 208, avenue des Apothicaires, 34298 Montpellier cedex 05, France; Fédération universitaire d'oncologie radiothérapie, ICM, institut régional du cancer de Montpellier, rue Croix-Verte, 34298 Montpellier cedex 05, France. Electronic address: david.azria@icm.unicancer.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hennequin</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Service de cancérologie-radiothérapie, AP-HP, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75475 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giraud</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Service d'oncologie radiothérapie, AP-HP, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France; Université de Paris, 20, rue Leblanc, 75015 Paris, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Compensation de la dose totale en cas d’interruption temporaire de radiothérapie externe dans le contexte de la pandémie de COVID-19 : mise au point pratique.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Cancer Radiother</MedlineTA><NlmUniqueID>9711272</NlmUniqueID><ISSNLinking>1278-3218</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName><SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName><QualifierName UI="Q000532" MajorTopicYN="N">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002289" MajorTopicYN="N">Carcinoma, Non-Small-Cell Lung</DescriptorName><QualifierName UI="Q000532" MajorTopicYN="N">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName><QualifierName UI="Q000532" MajorTopicYN="N">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000532" MajorTopicYN="Y">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="Y">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011471" MajorTopicYN="N">Prostatic Neoplasms</DescriptorName><QualifierName UI="Q000532" MajorTopicYN="N">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011853" MajorTopicYN="N">Radiobiology</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011879" MajorTopicYN="N">Radiotherapy Dosage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002583" MajorTopicYN="N">Uterine Cervical Neoplasms</DescriptorName><QualifierName UI="Q000532" MajorTopicYN="N">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D028761" MajorTopicYN="Y">Withholding Treatment</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Compensation</Keyword><Keyword MajorTopicYN="N">Dose totale</Keyword><Keyword MajorTopicYN="N">Radiotherapy</Keyword><Keyword MajorTopicYN="N">Radiothérapie</Keyword><Keyword MajorTopicYN="N">Total dose</Keyword><Keyword MajorTopicYN="N">Treatment duration</Keyword><Keyword MajorTopicYN="N">Étalement</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>04</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>04</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32307313</ArticleId><ArticleId IdType="pii">S1278-3218(20)30096-2</ArticleId><ArticleId IdType="doi">10.1016/j.canrad.2020.04.001</ArticleId><ArticleId IdType="pmc">PMC7146696</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rep Pract Oncol Radiother. 2015 Sep-Oct;20(5):328-39</Citation><ArticleIdList><ArticleId IdType="pubmed">26549990</ArticleId></ArticleIdList></Reference><Reference><Citation>Radiother Oncol. 1992 Aug;24(4):215-20</Citation><ArticleIdList><ArticleId IdType="pubmed">1410576</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2019 Jul 22;14(7):e0218627</Citation><ArticleIdList><ArticleId IdType="pubmed">31329602</ArticleId></ArticleIdList></Reference><Reference><Citation>Radiother Oncol. 2010 Jul;96(1):6-12</Citation><ArticleIdList><ArticleId IdType="pubmed">20400191</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Imaging Radiat Oncol. 2018 Feb;62(1):116-121</Citation><ArticleIdList><ArticleId IdType="pubmed">29030906</ArticleId></ArticleIdList></Reference><Reference><Citation>Radiother Oncol. 2020 Jan;142:210-216</Citation><ArticleIdList><ArticleId IdType="pubmed">31431371</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2005 Jan 1;23(1):11-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15545665</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Surg Oncol. 2020 Mar 17;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32185537</ArticleId></ArticleIdList></Reference><Reference><Citation>Radiat Oncol. 2018 May 16;13(1):96</Citation><ArticleIdList><ArticleId IdType="pubmed">29769103</ArticleId></ArticleIdList></Reference><Reference><Citation>Radiother Oncol. 2020 Feb;143:58-65</Citation><ArticleIdList><ArticleId IdType="pubmed">31439448</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Oncol. 2010 Mar;11(3):258-65</Citation><ArticleIdList><ArticleId IdType="pubmed">20138810</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Radiother. 2016 Sep;20 Suppl:S4-7</Citation><ArticleIdList><ArticleId IdType="pubmed">27521032</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Radiat Oncol Biol Phys. 2000 Jul 15;47(5):1165-7</Citation><ArticleIdList><ArticleId IdType="pubmed">10939883</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Radiol. 2000 Aug;73(872):892-4</Citation><ArticleIdList><ArticleId IdType="pubmed">11026867</ArticleId></ArticleIdList></Reference><Reference><Citation>JCO Clin Cancer Inform. 2017 Nov;1:1-15</Citation><ArticleIdList><ArticleId IdType="pubmed">30657372</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):667-71</Citation><ArticleIdList><ArticleId IdType="pubmed">15927409</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Rev Oncol Hematol. 2015 Mar;93(3):312-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25497158</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):654-61</Citation><ArticleIdList><ArticleId IdType="pubmed">17467926</ArticleId></ArticleIdList></Reference><Reference><Citation>Radiother Oncol. 2011 Aug;100(2):282-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21367477</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):516-7</Citation><ArticleIdList><ArticleId IdType="pubmed">10661362</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Radiat Oncol Biol Phys. 2006 Aug 1;65(5):1353-60</Citation><ArticleIdList><ArticleId IdType="pubmed">16765531</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Radiat Oncol Biol Phys. 2018 Mar 15;100(4):832-833</Citation><ArticleIdList><ArticleId IdType="pubmed">29485054</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2005 Jan 1;23(1):24-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15545669</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Oncol (R Coll Radiol). 2002 Oct;14(5):382-93</Citation><ArticleIdList><ArticleId IdType="pubmed">12555877</ArticleId></ArticleIdList></Reference><Reference><Citation>Radiother Oncol. 2011 Apr;99(1):6-11</Citation><ArticleIdList><ArticleId IdType="pubmed">21458088</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Oncol (R Coll Radiol). 1996;8(5):297-307</Citation><ArticleIdList><ArticleId IdType="pubmed">8934049</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Radiat Oncol Biol Phys. 1995 Jul 30;32(5):1275-88</Citation><ArticleIdList><ArticleId IdType="pubmed">7635767</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Radiother. 2020 Apr;24(2):87</Citation><ArticleIdList><ArticleId IdType="pubmed">32299663</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Radiat Oncol Biol Phys. 2018 Mar 15;100(4):841-842</Citation><ArticleIdList><ArticleId IdType="pubmed">29485058</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Radiat Oncol Biol Phys. 1993 Oct 20;27(3):493-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8226140</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer. 2005 Jul 15;104(2):240-50</Citation><ArticleIdList><ArticleId IdType="pubmed">15948160</ArticleId></ArticleIdList></Reference><Reference><Citation>Radiother Oncol. 1985 Jan;3(1):1-9</Citation><ArticleIdList><ArticleId IdType="pubmed">3975436</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2006 Mar 1;24(7):1057-63</Citation><ArticleIdList><ArticleId IdType="pubmed">16505424</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Languedoc-Roussillon</li><li>Occitanie (région administrative)</li><li>Île-de-France</li></region><settlement><li>Montpellier</li><li>Paris</li></settlement></list><tree><country name="France"><region name="Occitanie (région administrative)"><name sortKey="Azria, D" sort="Azria, D" uniqKey="Azria D" first="D" last="Azria">D. Azria</name></region><name sortKey="Giraud, P" sort="Giraud, P" uniqKey="Giraud P" first="P" last="Giraud">P. Giraud</name><name sortKey="Hennequin, C" sort="Hennequin, C" uniqKey="Hennequin C" first="C" last="Hennequin">C. Hennequin</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000125 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000125 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32307313
|texte= [Practical update of total dose compensation in case of temporary interruption of external radiotherapy in the COVID-19 pandemic context].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32307313" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidFranceV1
| This area was generated with Dilib version V0.6.37. |  |